Table 1.

Immune checkpoint inhibitors active in clinical trials

Immune checkpoint inhibitors	NCT identifier numbers	Combined therapy	Target	Allocation	Phase	Size	Primary ends	Status
Anti-PD-1/-L1	NCT03600883	AMG 510	KRASG12C	Randomized	Phase 1	733	AEs, DLTs, significant clinical changes	Recruiting
Atezolizumab	NCT04449874	GDC-6036 bevacizumab, cetuximab, rrlotinib	KRASG12C VGFR EGFR TKI	Non-randomized	Phase 1	236	AEs, DLTs	Recruiting
Pembrolizumab	NCT04429542	BCA101	EGFR/TGF-β	Non-randomized	Phase 1	292	Safety, Cmax, PFS, AEs, ORR, OS, DLTs, MTD	Recruiting
	NCT04613596	MRTX849	KRASG12D	N/A	Phase 2	120	Clinical activity	Recruiting
	NCT03785249	MRTX849	KRASG12D	N/A	Phase 1	565	Safety, tolerability, drug levels, molecular effects, and clinical activity	Recruiting
	NCT03299088	Trametinib	MEK	Non-randomized	Phase 1	15	DLTs, ORR, PFS	Active, not recruiting
	NCT02779751	Abemaciclib Anastrozole	CDK Estrogen synthesis	Non-randomized	Phase 1	100	PFS, AEs, ORR, OS, DCR, PK	Active, not recruiting
	NCT03948763	mRNA-5671/V941	Vaccine	Non-randomized	Phase 1	100	DLTs, AEs, ORR	Recruiting
	NCT04340882	Docetaxel Ramucirumab	Chemotherapy VEGFR	N/A	Phase 2	41	PFS, AEs, ORR, OS	Recruiting
	NCT03225664	Trametinib	MEK	N/A	Phase 1/2	37	ORR	Active, not recruiting
	NCT02492568	Radiation		N/A	Phase 2	96	ORR, toxicity	Complete
Nivolumab	NCT04263090	Rigosertib	PLK1	N/A	Phase 1/2	30	MTD, ORR, PFS, OS	Recruiting
	NCT02852083	Pioglitazone Clarithromycin	PPARγ Bacteria proteins	Randomized	Phase 2	86	PFS, AEs, ORR, OS	Unknown status
	NCT02492568	Ipilimumab	Anti-CTLA-4	N/A	Phase 3	1980	OS, ORR, disease related symptom	Recruiting
SHR-1210	NCT03083041	Apatinib	Anti-VEGFR	N/A	Phase 2	117	AEs, ORR	N/A

AEs: Adverse events; DLTs: dose-limiting toxicities; PFS: progression-free survival; OR: overall survival; RR: response rate; MTD: maximum tolerant doses; ORR: objective response rate; DCR: disease control rate; PK: pharmacokinetics; Cmax: plasma concentration.